AYTU — Aytu Biopharma Income Statement
0.000.00%
Last trade - 00:00
- $16.66m
- $13.62m
- $107.40m
- 56
- 95
- 69
- 85
2019 June 30th | 2020 June 30th | 2021 June 30th | R2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 7.32 | 27.6 | 65.6 | 96.7 | 107 |
Cost of Revenue | |||||
Gross Profit | 5.12 | 20.1 | 29.2 | 52.3 | 66.6 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 34 | 38.6 | 126 | 206 | 124 |
Operating Profit | -26.7 | -11 | -60.4 | -110 | -17.1 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -27.1 | -13.6 | -58 | -109 | -17.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | -27.1 | -13.6 | -58.3 | -109 | -17.1 |
Net Income Before Extraordinary Items | |||||
Net Income | -27.1 | -13.6 | -58.3 | -109 | -17.1 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -27.1 | -13.6 | -58.3 | -109 | -17.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -444 | -104 | -52.4 | -40.7 | -3.4 |